Hemogenyx Pharmaceuticals Plc (HEMO.L)
GBp 320.0
(-8.57%)
GBp 320.0
(-8.57%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -6.02 Million | -2.91 Million | -2.62 Million | -1.79 Million | -1.19 Million | -1.35 Million |
| Net Income | -6.69 Million | -3.98 Million | -5.1 Million | -2.09 Million | -1.45 Million | -1.47 Million |
| Depreciation & Amortization | 645.68 Thousand | 195.24 Thousand | 126.34 Thousand | 106.75 Thousand | 94.72 Thousand | 51.8 Thousand |
| Deferred income taxes | - | - | -18.02 Thousand | -146.77 Thousand | 20.74 Thousand | - |
| Stock-based compensation | 242.84 | 17.57 Thousand | 153.35 Thousand | 363.1 Thousand | 122.48 Thousand | 242.53 Thousand |
| Change in working capital | -833.59 Thousand | 242.59 Thousand | 101.38 Thousand | -56.51 Thousand | -1824.00 | -117.93 Thousand |
| Other non-cash items | 2.14 Million | 620.96 Thousand | 2.11 Million | 30.04 Thousand | 17.13 Thousand | -51.59 Thousand |
| Investing Cash Flow | -117.28 Thousand | -420.25 Thousand | -938.95 Thousand | -169.68 Thousand | 2273.00 | -20.22 Thousand |
| Investments in PPE | -117.28 Thousand | -428.94 Thousand | -817.99 Thousand | -173.04 Thousand | -11.91 Thousand | -24.58 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | -1908.00 | -138.91 Thousand | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 85.34 | 10.59 Thousand | 17.95 Thousand | 3365.00 | 14.19 Thousand | 4368.00 |
| Financing Cash Flow | 4.44 Million | -110.14 Thousand | 8.77 Million | 3.21 Million | -39.39 Thousand | 1.18 Million |
| Debt repayment | -638.77 | -110.14 | -3.18 Million | -461.77 Thousand | -39.39 | -1.17 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 5.08 Million | - | 12 Million | 3.18 Million | - | 4993.00 |
| Other Financing Activities | 5088.08 | -110.03 Thousand | -39.07 Thousand | 490.52 Thousand | -39.35 Thousand | 1.17 Million |
| Accounts receivables | 4469.00 | -2109.00 | -196.68 Thousand | -21.39 Thousand | 16.05 Thousand | -19.26 Thousand |
| Accounts payables | 28.57 Thousand | -27.12 Thousand | 298.07 Thousand | -35.73 Thousand | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -838.06 Thousand | 271.81 Thousand | - | 623.00 | -17.88 Thousand | -98.67 Thousand |
| Cash at beginning of period | 2.53 Million | 6.84 Million | 1.81 Million | 498.67 Thousand | 1.76 Million | 1.87 Million |
| Cash at end of period | 1.24 Million | 2.53 Million | 6.84 Million | 1.81 Million | 498.67 Thousand | 1.76 Million |
| Capital Expenditure | -117.28 Thousand | -428.94 Thousand | -817.99 Thousand | -173.04 Thousand | -11.91 Thousand | -24.58 Thousand |
| Effect of forex changes on cash | 403.04 Thousand | -876.2 Thousand | -182.71 Thousand | 69.68 Thousand | -26.75 Thousand | 77.81 Thousand |
| Net cash flow / Change in cash | -1.28 Million | -4.3 Million | 5.02 Million | 1.31 Million | -1.26 Million | -114.22 Thousand |
| Free Cash Flow | -6.13 Million | -3.33 Million | -3.44 Million | -1.97 Million | -1.21 Million | -1.37 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1406.42 | -1406.42 | -1184.79 | -6.69 Million | -1184.79 | -4.32 Million |
| Depreciation & Amortization | 160.84 | 160.84 | 162.89 | 645.68 Thousand | 162.89 | 319.9 Thousand |
| Deferred income taxes | - | - | - | - | - | -634.23 Thousand |
| Stock-based compensation | - | - | 101.18 | 242.83 Thousand | 101.18 | 20.24 |
| Change in working capital | 49.33 | 49.33 | -420.95 | -833.59 Thousand | -420.95 | -40.99 Thousand |
| Other non-cash items | 20.83 | 20.83 | -18.58 | 2.14 Million | -18.58 | 1.34 Million |
| Investing Cash Flow | 8.66 | 8.66 | -36.74 | -117.28 Thousand | -36.74 | -13.16 Thousand |
| Investments in PPE | 2.00 | - | -52.06 | -117.28 Thousand | -52.06 | -13.16 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 8.66 | 8.66 | 15.32 | 85.34 | 15.32 | 27.35 |
| Financing Cash Flow | 1421.31 | 1421.31 | 424.74 | 4.44 Million | 424.74 | 3.59 Million |
| Debt repayment | - | - | - | -638.77 | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 3.16 Million | - | 1.17 Million | 5.08 Million | - | 3.91 Million |
| Other Financing Activities | 1421.31 | 1421.31 | 424.74 | 5088.08 | 424.74 | 1799.91 |
| Accounts receivables | -0.01 | -0.01 | -0.57 | 4469.00 | -0.57 | 5600.00 |
| Accounts payables | - | - | - | 28.57 Thousand | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 49.34 | 49.34 | -420.39 | -838.06 Thousand | -420.39 | -46.59 Thousand |
| Cash at beginning of period | 1.24 Million | - | 3.08 Million | 2.53 Million | - | 2.53 Million |
| Cash at end of period | 1.64 Million | 197.58 | 1.24 Million | 1.24 Million | -918.63 | 3.08 Million |
| Capital Expenditure | 2.00 | - | -52.06 | -117.28 Thousand | -52.06 | -13.16 Thousand |
| Effect of forex changes on cash | -56.98 | -56.98 | 53.62 | 403.04 Thousand | 53.62 | 147.90 |
| Net cash flow / Change in cash | 395.16 Thousand | 197.58 | -1.83 Million | -1.28 Million | -918.63 | 552.09 Thousand |
| Free Cash Flow | -1173.41 | -1175.41 | -1412.31 | -6.13 Million | -1412.31 | -3.34 Million |
FFB
FMCCT
2136
ARDX
PMTA
3563